Skip to main content
OpenTrials
Completed

NCT Number: NCT07125014

Frequency and Predictors of Post-ERCP Pancreatitis in a South Asian Tertiary Care Center

This study was conducted at the Department of Gastroenterology, Lady Reading Hospital, Peshawar, Pakistan, from January 2023 to December 2023. It aimed to determine how often patients develop pancreatitis (inflammation of the pancreas) after undergoing a procedure called endoscopic retrograde cholangiopancreatography (ERCP), and to identify the main factors that increase this risk. We reviewed the medical records of 300 adult patients who had ERCP for various conditions, such as bile duct stones, tumors, and strictures. We assessed patient characteristics, procedure details, and laboratory results to see which factors were linked to post-ERCP pancreatitis. The study found that prolonged cannulation time, injection of contrast into the pancreatic duct, and high levels of C-reactive protein before the procedure were the strongest predictors of this complication. These findings may help doctors identify high-risk patients and take preventive steps to reduce the chances of pancreatitis after ERCP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-ERCP Pancreatitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

LRH/MTI

Peshawar, KPK, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Known chronic pancreatitis
  • Pancreatic malignancy
  • Pre-existing acute pancreatitis
  • Incomplete procedural or laboratory records

Exclusion criteria

  • Known chronic pancreatitis
  • Pancreatic malignancy
  • Pre-existing acute pancreatitis
  • Incomplete procedural or laboratory records

Treatment and study plan

observational study

Procedure

This is an observational study with no experimental or therapeutic interventions administered to participants. All data were collected retrospectively from existing hospital records for patients who underwent ERCP between January 2023 and December 2023 at Lady Reading Hospital, Peshawar. No drugs, devices, or procedures were assigned to participants as part of this research.

Primary outcomes

  1. Incidence of Post-ERCP Pancreatitis

    Time frame: Within 24 hours after ERCP and during hospitalization

    The number and proportion of patients developing post-ERCP pancreatitis (PEP), defined as new or worsened abdominal pain with serum amylase or lipase levels ≥3 times the upper limit of normal within 24 hours after ERCP, requiring hospitalization or prolongation of hospital stay.

Sponsors and collaborators

Lead sponsor

Nangarhar University

Other

Registry information

Official study title

Frequency and Risk Factors of Post-ERCP Pancreatitis: A Single-Center Experience From South Asia

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 15, 2025
Registry last updated
Aug 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.